NCT03677596 2023-11-22A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible PatientsPfizerPhase 4 Completed102 enrolled 27 charts